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Aims The purpose of this study was to evaluate the Genous
TM endothelial progenitor cell capturing stent vs. the Taxus
Liberte ´ paclitaxel-eluting stent in patients with de novo coronary lesions with a high-risk of coronary restenosis.
Methods
and results
We randomly assigned 193 patients with lesions carrying a high risk of restenosis to have the Genous stent or the
Taxus stent implanted. Lesions were considered high risk of restenosis if one of the following applied: chronic total
occlusion, lesion length .23 mm, vessel diameter ,2.8 mm, or any lesion in a diabetic patient. At 1-year, the rate of
the primary end point, target vessel failure (TVF), was 17.3% in the Genous stent group when compared with 10.5%
in the Taxus stent group [risk difference (RD) 6.8%, 95% CI 23.1 to 16.7%], a difference predominantly due to a
higher incidence of repeat revascularization in patients treated with the Genous stent. In contrast, no stent throm-
bosis was observed in the Genous stent group compared to 4 stent thromboses in the Taxus stent group (RD
24.2%; 95% CI 210.3 to 0.3%). Repeat angiography between 6 and 12 months in a subgroup of patients showed
a signiﬁcantly higher late loss in the Genous stent compared with the Taxus stent (1.14+0.64 and 0.55+0.61 mm).
Conclusion In patients with lesions carrying a high risk of restenosis, the Genous stent resulted in a non-signiﬁcant higher rate of
TVF compared with the Taxus stent mainly due to more repeat revascularizations in the Genous stent group. There
were four stent thromboses with Taxus stent, none with the Genous stent.
-----------------------------------------------------------------------------------------------------------------------------------------------------------
Keywords Stent † Genous † Taxus † Restenosis † Percutaneous coronary intervention
Introduction
Drug-eluting stents (DES) have demonstrated a marked reduction
in in-stent restenosis compared with bare metal stents (BMS) in
the treatment of coronary artery disease.
1–5 In order to reduce
neointimal hyperplasia after DES placement, the antiproliferative
drug induces a cytostatic or cytotoxic effect on the neointimal vas-
cular tissue. However, this also impedes the natural healing
response by delaying the formation of a functional endothelial
layer covering the stent.
6,7 In DES, a prolonged absence of
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occurrence of late and very late stent thrombosis, and currently,
long-term dual antiplatelet therapy is recommended.
7
Rather than locally intervene with cytotoxic or cytostatic
drugs, accelerated vascular healing with rapid establishment of a
functional endothelial layer after vascular injury has been shown
to assist in the prevention of neointimal proliferation and
thrombus formation after stent placement.
8,9 The GenousTM
endothelial progenitor cell (EPC) capturing stent is coated with
anti-human CD34þ antibodies that bind circulating EPCs from
the peripheral blood to the stent surface. In the animal model,
scanning electron microscopic images have demonstrated a com-
plete re-endothelialization of the stent struts and vessel segments
within only a few hours following Genous stent placement.
10 It is
hypothesized that these ‘captured’ EPCs can rapidly differentiate
into a functional endothelial layer on the stent surface. The
safety and feasibility of the Genous stent was evaluated in the
non-randomized HEALING FIM registry
11 and HEALING II
study
12,13 in patients with de novo coronary artery disease. Pre-
liminary results of the world-wide e-HEALING registry have
shown low repeat revascularization and low incidence of stent
thrombosis.
14 Thus far, randomized data of the attractiveness of
the Genous stent in terms of rapid endothelialization to
prevent repeat revascularization are lacking. This is the ﬁrst ran-
domized, single-centre study that compares the GenousTM EPC
capturing stent with the Taxus Liberte ´ paclitaxel-eluting stent,
evaluating the efﬁcacy and feasibility of the treatment of coronary
artery lesions in patients with a high risk of restenosis.
Methods
Study design and patient population
The investigator-initiated single-centre TRI-stent Adjudication Study
(TRIAS) study was a prospective, randomized, single-blind study per-
formed in a high-volume centre with on-site cardiac surgery. The
study complied with the principles of the Declaration of Helsinki
regarding investigation in humans and was approved by the local insti-
tutional review board. The study was conducted from February 2006
to April 2007. The duration of follow-up is 5 years and here we report
the 1 year outcome.
For the purpose of this study, coronary lesions were marked as
carrying a high risk for restenosis if at least one of the following
applied: (i) a chronic coronary artery occlusion; (ii) a coronary
artery stenosis with a length of more than 23 mm; (iii) a lesion in
a coronary artery with a diameter of less than 2.8 mm by visual esti-
mation; (iv) or any lesion in a diabetic patient. All other lesions were
considered to be low-risk lesions. Patients accepted to undergo a
non-urgent stent placement for de novo coronary artery stenosis
with a high risk for restenosis were eligible for inclusion. All patients
had either stable angina despite medical therapy, unstable angina pec-
toris or a non-ST-segment elevation myocardial infarction (MI). All
patients were on statin therapy for at least 7 days prior to procedure,
regardless of the type or dose of statins. Major exclusion criteria
were recent ST-segment elevation MI (within the previous 72 h);
unstable ventricular arrhythmia; severe renal (serum creatinin .
200 mg/L) or liver insufﬁciency; severe hypertension (systolic blood
pressure . 180 mmHg or diastolic blood pressure over 100 mmHg,
after treatment); current therapy of immune-suppression,
chemotherapy or radiotherapy, known immunosuppressive or auto-
immune disease; previous administration of murine therapeutic anti-
bodies or exhibited sensitization through the production of human
anti-murine antibodies; contraindication to aspirin, heparin, clopido-
grel, or any other drug related to this study; planned surgery
within the ﬁrst 6 months after the procedure that will require discon-
tinuation of either aspirin or clopidogrel.
Study procedure
Written informed consent was obtained after the patient had been
accepted for elective and non-urgent PCI. The angiographic in- and
exclusion criteria were reassessed after initial angiography at the
start of the procedure. All high-risk lesions were identiﬁed and
recorded as such. After at least one high-risk lesion was identiﬁed,
patients were randomly assigned in a single-blinded manner for treat-
ment with a Genous stent or a Taxus stent in a 1:1 ratio. Randomiz-
ation was performed using a sealed and signed envelope which was
blinded to all study personnel. Randomization blocks were created
with randomly chosen block sizes of one, two, three, or four.
Low-risk lesions could be treated during the same procedure accord-
ing to the treatment assignment or with a BMS.
Lesions were treated in accordance with standard PCI guidelines.
Pre- and post-dilatation were left at the discretion of the operator.
At the start of the procedure patients received heparin 5000 IU. The
use of intravenous platelet glycoprotein IIb/IIIa inhibitors was at the dis-
cretion of the operator. Patients were treated with aspirin 100 mg
indeﬁnitely. Clopidogrel was administered in a loading dose 300 mg
directly before or after the procedure and was recommended
(75 mg/day) for at least 1 month after Genous stent and at least
6 months after a Taxus stent implantation.
GenousTM endothelial progenitor cell
capturing stent
The Genous stent comprises a covalently coupled polysaccharide
matrix coating with monoclonal murine anti-human CD34þ anti-
bodies on the adluminal stent surface, attached to a 316L stainless
steel stent (Genous Bio-engineered R stentTM, OrbusNeich Medical
Technologies, Fort Lauderdale, FL, USA). These anti-CD34þ anti-
bodies speciﬁcally target the circulating EPC population associated
with post-natal neoangiogenesis and arterial repair response. The
Genous stent received CE mark on 11 August 2005.
Taxus Liberte ´ paclitaxel-eluting stent
The Taxus Liberte ´TM-SR Paclitaxel-Eluting Coronary Stent (Boston
Scientiﬁc, MA, USA) is a 316L stainless steel stent coated with a
drug/polymer formulation consisting of paclitaxel and TransluteTM
Polymer Carrier. The polymer is mixed with the drug paclitaxel and
then applied to the stents. There is no primer or topcoat layer. The
drug/polymer coating is adhered to the entire surface (i.e. luminal
and abluminal) of the stent.
Follow-up
Patients were scheduled for a hospital visit at 30 days, 6 months and
1 year. At the patient’s request, the hospital visit could be replaced
by a telephone call. Patients were asked speciﬁc questions about the
interim development of angina according to the Canadian Cardiovas-
cular Society Classiﬁcation of stable angina and Braunwald Classiﬁ-
cation of unstable angina. They were also monitored for major
adverse cardiac events and the need for additional revascularizations
of the index target lesions. If a major adverse cardiac event was
reported, we reviewed hospital and chart records and contacted the
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plete information. All patients were invited for repeat coronary angio-
graphy between 6 and 12 months; however, participation of
angiographic follow-up was not mandatory for inclusion in the study.
Quantitative coronary analysis
Coronary angiograms were obtained pre-procedural, post-procedural,
and at follow-up (between 6 and 12 months) in at least two orthogonal
projections after intracoronary injection of nitroglycerin. Off-line
quantitative coronary analyses (QCAs) were performed by an inde-
pendent core laboratory (Angiographic Core Laboratories, Cardiovas-
cular Research Foundation, NY, USA) with observers blinded to the
allocated stent. Images were analyzed using MEDIS QCA software
version 6.0 (MEDIS, Leiden, The Netherlands). The tip of a 6 or 7
French catheter ﬁlled with contrast was used for calibration. The
minimal lumen diameter (MLD) was measured at the narrowest
point of the lesion or within the stent. Late lumen loss was deﬁned
as the difference between MLD after the procedure and at follow-up.
Endpoints and deﬁnitions
The primary endpoint was target vessel failure (TVF) deﬁned as the
composite of cardiac death, MI (unless documented to arise from
the non-treated coronary artery), and target vessel revascularization
(TVR) within 1 year. All deaths were considered cardiac death
unless otherwise documented. Peri-procedural MI was deﬁned as a
rise in the creatine kinase-MB level or troponin T level of more than
three times the upper limit of normal. Myocardial infarction (spon-
taneous) was deﬁned as any rise in the creatine kinase-MB level or tro-
ponin T level above the upper reference limit. Target vessel
revascularization was deﬁned as any repeat revascularization of the
target vessel by repeat percutaneous intervention or coronary artery
bypass grafting (CABG). All events unequivocally not related to ran-
domized (high-risk) lesions were excluded from the primary endpoint.
Secondary endpoints included non-cardiac death, target lesion
revascularization (TLR), non-TVR, and stent thrombosis within
1 year after the index procedure. All endpoint deﬁnitions used are
in accordance with the Academic Research Consortium.
15 The
primary endpoints were adjudicated by an independent clinical event
committee, with members blinded to the assigned stent.
Statistical analysis
Originally, the study was designed as a non-inferiority study. Based on
the results of the TAXUS IV trial (TVF rate of 10% at 1-year follow-up
in the Taxus stent group) and the preliminary results of the
e-HEALING registry, the assumed incidence of the primary endpoint
was 10% at 1 year with an upper limit for non-inferiority of 16% in
the Genous stent group. For this purpose, 620 patients would have
been needed to provide the study with 80% power with a one-sided
a of 5%. The enrolment in the study was discontinued after
193 patients had been included. At that time, the decision had been
made to venture into a large, international, multicentre study with a
similar study design (TRIAS HR trial: ISRCTN 74297220). Thus, the
original power calculation does not apply to the current pilot study
of 193 patients.
For the primary and secondary endpoints, no formal hypothesis
testing was performed. Henceforth, for all endpoints, the cumulative
risk differences (RDs) and the 95% conﬁdence intervals (CIs) are pre-
sented for descriptive purposes only. For baseline characteristics, con-
tinuous variables with normal distributions were expressed as
means+SD and were compared with the use of an unpaired Student’s
t-test. Categorical variables were compared with the use of the x
2 test
or Fisher’s exact test, where appropriate. The occurrence of the
primary endpoint, TVF, over time is presented using the Kaplan–
Meier method. Because no formal test was performed on the
Kaplan–Meier curves, we present the 1-year cumulative RD and
95% CI. The percentage of patients on dual antiplatelet therapy was
presented using the Kaplan–Meier method. The difference in the
use of dual antiplatelet therapy between the groups was tested using
the log-rank test, thus giving equal weight to the group differences
observed at each time point. Only clinical events conﬁrmed by the
Clinical Event Committee were taken into account for the analysis
of primary endpoint. For all statistical analyses, we used the SPSS soft-
ware package (version 15, SPSS Inc., Chicago, IL, USA).
Results
Baseline patient and lesion characteristics
Between February 2006 and April 2007, 193 patients were ran-
domized to either a Genous stent (n ¼ 98) or a Taxus stent
(n ¼ 95). As shown in Table 1, the two groups were similar with
respect to all variables examined with the exception of diabetic
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Table 1 Baseline characteristics of patients
Randomized to P-value
Genouos
(n 5 98)
Taxus
Liberte ´
(n 5 95)
Age (years) 62+10 63+11 0.657
Male 72 (73%) 70 (74%) 0.973
Diabetes 14 (14%) 26 (27%) 0.025
NIDDM 11 (11%) 18 (19%) 0.715
IDDM 3 (3%) 8 (8%)
Hypertension 45 (46%) 53 (56%) 0.17
Hyperlipidaemia 62 (63%) 50 (53%) 0.135
Family history of CAD 52 (53%) 61 (64%) 0.116
Current smoker 32 (33%) 30 (32%) 0.244
Prior myocardial
infarction
37 (38%) 39 (41%) 0.639
Prior percutaneous
intervention
25 (26%) 25 (26%) 0.898
Prior CABG 3 (3%) 3 (3%) 0.969
Angina pectoris
Stable 80 (82%) 81 (85%) 0.498
Unstable 18 (18%) 14 (15%)
Statin therapy 98 (100%) 93 (98%) 0.241
Number of high-risk
lesions treated
1 78 (80%) 71 (75%) 0.519
2 17 (17%) 18 (19%)
3 3 (3%) 6 (6%)
Values are n (%) or mean+SD.
(N)IDDM (non)-insulin-dependent diabetes mellitus; CAD, coronary artery
disease; CABG, coronary artery bypass grafting.
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shown in Table 2 and were well matched except for the percentage
of vessels ,2.8 mm treated which was higher in the Taxus stent-
treated group. Overall, more than 80% of the randomized lesions
were longer than 23 mm and nearly 30% of the lesions were
chronic total occlusions. As a result of lesion and patient selection,
a total of 89% of the treated high-risk lesions were class B2 or C
type lesions according to the American College of Cardiology–
American Heart Association classiﬁcation.
Procedural characteristics
All randomized high-risk lesions were treated according to the ran-
domized assignment. The number of stents implanted per patient,
the mean total stent length and post-procedural lesion diameter,
and other deployment and implantation variables were similar in
the two groups (Table 2). Peri-procedural administration of glyco-
protein IIb/IIIa inhibitors did not differ between both groups (11%
Genous stent vs. 16% Taxus stent; P ¼ NS). In the Genous stent
group, 5 out of 18 low-risk lesions were treated with a BMS and
in the Taxus stent group 8 out of 17.
Clinical outcomes
Clinical follow-up was complete for all patients and events are
listed in Table 3. The rate of the primary endpoint, TVF at 1
year, was 17.3% in the Genous stent group when compared with
10.5% in the Taxus stent group (RD 6.8%, 95% CI 23.1 to
16.7%). A Kaplan–Meier curve of event-free survival of TVF is
shown in Figure 1. The cumulative rate of cardiac death or MI at
1 year was 3.1% in the Genous stent group when compared
with 5.3% in the Taxus stent group (RD 22.2%, 95% CI 24.9
to 14.4%). During 1-year follow-up, no cases of cardiac death
were observed in each treatment arm. Three patients (3.1%) in
the Genous stent group and two patients (2.1%) in the Taxus
stent group had a peri-procedural MI. In the Genous stent
group, one patient had an occlusive dissection and one patient
had a side branch occlusion. The third patient had recurrence of
angina and underwent repeat angiography which showed a
patent stent in the proximal RCx with TIMI 2 ﬂow. This patient
was treated with platelet glycoprotein IIb/IIIa inhibitor and
heparin. In the Taxus stent group, both patients had an occlusive
dissection. A total of three Taxus stent-treated patients had a
spontaneous MI attributable to a stent thrombosis and one
patient had a deﬁnite stent thrombosis which did not resulted in
an MI. All patients who had a deﬁnite stent thrombosis were on
dual antiplatelet therapy at the time of the event. No deﬁnite
stent thrombosis was observed in the Genous stents, resulting in
a numerical difference as compared to the Taxus stent (RD
24.2%; 95% CI 210.3 to 0.3%). The characteristics of patients
with a deﬁnite stent thrombosis are summarized in Table 4. Note-
worthy, as a result of the recommendations, the percentage of
patients on dual antiplatelet therapy was signiﬁcantly lower in
the Genous stent group when compared with the Taxus stent
group and is shown in Figure 2 as a Kaplan–Meier curve.
Target lesion revascularization by PCI was performed in
12 patients (12.2%) treated with a Genous stent and in 8 patients
(8.4%) with a Taxus stent (RD 3.8%, 95% CI 24.7 to 12.4%). In
each treatment arm, one patient underwent a TLR by CABG. In
the Genous stent group, two patients whom underwent CABG
had patent stents as assessed by a pre-operative coronary angio-
gram and were considered as a non-TVR. The 1-year cumulative
rate of cardiac death, MI or TLR was 15.3% in the Genous stent
group when compared with 10.5% in the Taxus stent group (RD
4.8%, 95% CI 29.0 to 4.1%).
In the Genous stent group, one patient died from a sepsis
323 days after the index procedure. Two patients died in the
Taxus stent group, the ﬁrst from a pancreatic carcinoma
243 days after the index procedure and the second from a liver
carcinoma at 338 days. The 1-year rate of non-TVR was 8.2% in
the Genous stent group and 14.7% in the Taxus stent group
(RD 26.5%, 95% CI 215.5 to 2.4%). In both groups, a non-TVR
associated deﬁnite sub acute stent thrombosis occurred. No
repeat revascularizations were performed in low-risk lesions in
either group.
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Table 2 Baseline angiographic and procedural
characteristics of high-risk lesions
Randomized to P-value
Genous
(L 5 121)
Taxus Liberte ´
(L 5 125)
Type of lesion
a
A 0 (0%) 2 (2%) 0.295
B1 10 (8%) 15 (12%)
B2 54 (45%) 52 (42%)
C 57 (47%) 56 (45%)
Chronic total
occlusion
39 (32%) 30 (24%) 0.151
Lesion length
.23 mm
101 (83%) 100 (80%) 0.481
Vessel diameter
,2.8 mm
9 (7%) 25 (20%) 0.004
Bifurcated lesions 21 (17%) 23 (18%) 0.831
Target coronary
artery
Left main 1 (1%) 1 (1%) 0.86
Left anterior
descending
48 (40%) 46 (37%)
Left circumﬂex 31 (26%) 29 (23%)
Right coronary
artery
41 (34%) 49 (39%)
Pre-dilatation
performed
108 (89%) 111 (89%) 0.909
Stent length (mm) 31.7+14.3 30.7+12.0 0.561
Stent diameter (mm) 3.3+0.4 3.2+0.5 0.438
Stents per lesion 1.2+0.5 1.2+0.5 0.826
Post-dilatation
performed
88 (73%) 88 (70%) 0.686
Procedural success 119 (98%) 124 (99%) 0.617
Values are n (%) or mean+SD; L, number of lesions.
aAccording to ACC-AHA classiﬁcation.
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Angiographic follow-up was available in 90 patients (47%) and the
median time of angiographic follow-up was 8 months (5–13
months). In the Genous stent group, angiographic follow-up was
available for 53 patients: 37 patients (70%) had 1 lesion, 15 patients
(28%) had 2 lesions and, 1 patient (2%) had 3 lesions, amounting to
a total of 70 high-risk lesions. In the Taxus stent group, angio-
graphic follow-up was available for 37 patients: 24 patients (65%)
had 1 lesion, 10 patients (27%) had 2 lesions, 3 patients (8%)
had 3 lesions, amounting to a total of 53 high-risk lesions. The per-
lesion QCA results of the high-risk lesions of all patients with
angiographic follow-up are summarized in the left panel of
Table 5. In the MLD, pre- and post-procedure was comparable
between the Genous stent arm and the Taxus stent arm. At
follow-up, mean MLD was signiﬁcantly smaller in the Genous
stent arm compared with the Taxus stent arm, 1.48+0.73 vs.
2.06+0.69 mm, respectively (P , 0.0001).
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Table 3 One-year clinical follow-up
Randomized to Risk difference 95% CI
Genous (n 5 98) Taxus Liberte ´ (n 5 95)
Primary endpoint
TVF (composite of cardiac death, MI, or TVR) 17 (17.3%) 10 (10.5%) 6.8% 23.1 to 16.7%
Other composite endpoints
Cardiac death, MI, or TLR 15 (15.3%) 10 (10.5%) 4.8% 29.0 to 4.1%
Cardiac death or MI 3 (3.1%) 5 (5.3%) 22.2% 24.9 to 14.4%
Components of the primary endpoint
Cardiac death 0 0 0% —
Myocardial infarction
Peri-procedural 3 (3.1%) 2 (2.1%) 1.0% 23.5 to 5.4%
Spontaneous 0 3 (3.2%) 23.2% 26.7 to 3.6%
TLR
Percutaneous 12 (12.2%) 8 (8.4%) 3.8% 24.7 to 12.4%
Surgical 1 (1.0%) 1 (1.1%) 20.1% 22.9 to 2.8%
TVR/no TLR
Percutaneous 0 0 0% —
Surgical 2 (2.0%) 0 2.0% 20.8 to 4.8%
Stent thrombosis of a target lesion
Deﬁnite 0 4 (4.2%) 24.2% 210.3 to 0.3%
Probable 0 0 0% —
Possible 0 0 0% —
Other events
Non-cardiac death 1 (1.0%) 2 (2.1%) 21.1% 24.6 to 2.4%
MI not related to a target lesion 1 (1.0%) 1 (1.1%) 20.1% 22.9 to 2.8%
Non-TVR
Percutaneous 8 (8.2%) 14 (14.7%) 26.5% 215.5 to 2.4%
Surgical 0 0 0% —
Stent thrombosis not related to a target lesion 1 (1.0%) 1 (1.1%) 1.1% 22.9 to 2.8%
Values are n (%) or mean+SD; CI, conﬁdence interval; TVF, target vessel failure; MI, myocardial infarction; TLR, target lesion revascularization; TVR, target vessel
revascularization.
Figure 1 Kaplan–Meier curve. Event-free survival of target
vessel failure among patients who received a Genous stent and
those who received a Taxus Liberte ´ stent.
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stent arm compared with the Taxus stent arm, 1.14+0.64 vs.
0.55+0.61 mm, respectively (P , 0.0001). Figure 3 shows the
cumulative distribution frequency curve of percentage diameter
stenosis at pre-, post-procedure, and at follow-up for each of
the treatment arm. The results of a per-patient QCA analysis
using the mixed model were virtually the same as the results
of the per lesion analysis (see Supplementary material online,
Table S6).
The middle and right panels of Table 5 show the per-lesion QCA
analyses when restricted to patients with clinically driven repeat
coronary angiography (middle panel) and patients with non-
clinically driven repeat angiography (right panel). In patients with
clinically driven repeat coronary angiography, late loss was signiﬁ-
cantly higher in the Genous stent arm compared with the Taxus
stent arm (1.40+0.65 vs. 0.60+0.54 mm; P ¼ 0.002). Similar
ﬁndings were found in patients with non-clinically driven angiogra-
phy (late loss Genous stent 1.03+0.60 vs. late loss Taxus stent
0.54+0.62 mm; P , 0.0001).
Patients with angiographic follow-up were younger (60+10 vs.
64+11, P ¼ 0.01), had more often two high-risk lesions treated
(28 vs. 10%, P ¼ 0.01), had less often a lesion length .23 mm at
baseline (76 vs. 88%, P ¼ 0.01), and had a different distribution
of the target coronary artery (see Supplementary material
online, Tables S7 and S8).
Discussion
In this single-centre, randomized pilot study, the Genous stent was
compared with a second-generation Taxus stent for treatment of
coronary artery lesions with a high risk of restenosis. The main
ﬁndings of this study were that at 1 year, a non-signiﬁcant trend
towards a higher rate of TVF was observed in the Genous stent
group compared to the Taxus stent group. In contrast, with only
1 month of dual antiplatelet therapy recommended, no deﬁnite
stent thrombosis was observed in the Genous stent group com-
pared with four cases in the Taxus stent group. This is the ﬁrst ran-
domized study comparing the outcome of the Genous stent with
the Taxus stent.
The use of DES in complex lesions was evaluated in the TAXUS
VI study
16,17 in which 446 patients with long, complex lesions were
randomized to treatment with either a Taxus stent or an equival-
ent BMS. Of all lesions, 56% were classiﬁed as complex lesions and
mean lesion length was 20.6 mm, with a mean stent length of
33.4 mm. In the Taxus stent group, the 1-year rate of TVF was
16.4% and TLR was 8.3%. We included fewer diabetic patients
but more type B2 and type C complex lesions compared with
the TAXUS VI study. The 1-year TVF rate of the Genous stent
group was comparable to the Taxus stent group of the TAXUS
VI study. However, in our Taxus stent group, a lower rate of
TVF was observed. This difference may be partly explained by
the high incidence of MI in the Taxus stent group of the TAXUS
IV. Furthermore, repeat angiography was performed in all Taxus
stent patients in TAXUS VI which could have increased
the rate of TVR due to angiography-driven revascularizations
(occulo-stenotic reﬂex). Recently, the Genous stent was evaluated
in a small, non-randomized registry
18 including 80 consecutive
patients who had two or more of the following high-risk features:
diabetes mellitus, unstable coronary syndromes, left ventricular
dysfunction, multi-interventions, or B2/C lesions. At 14 months
follow-up TLR was 13%, but ischaemia-driven TLR was 5%,
whereas the remaining 8% was treated for severity of angiographic
restenosis and not because of recurrence of symptoms. The rate of
TVF was 16% and, of interest, no cases of deﬁnite stent throm-
boses were observed. In general, patient characteristics were
...............................................................................................................................................................................
Table 4 Characteristics of the patients with a deﬁnite stent thrombosis
Patient Stent type Days Lesion location DAT at time
of event
Outcome Repeat
revascularization
64-year old male Taxus Liberte ´ ,1 proximal RCA Yes MI (CK-MB more than
three times ULN)
Yes, balloon angioplasty
41-year old male Taxus Liberte ´ 9 proximal RCA Yes no MI Yes, stent placement
54-year old female Taxus Liberte ´ 104 proximal LAD Yes MI (CK-MB more than
three times ULN)
Yes, balloon angioplasty
57-year old male Taxus Liberte ´ 206 Mid-LAD Yes MI (CK-MB more than
three times ULN)
Yes, balloon angioplasty
RCx, ramus circumﬂex; RCA, right coronary artery; LAD, left anterior descending; DAT, dual antiplatelet therapy; MI, myocardial infarction; ULN, upper limit of normal.
Figure 2 Kaplan–Meier curve. Percentage of patients on dual
antiplatelet therapy during 1-year follow-up.
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Table 5 Results of the per lesion quantitative coronary analyses of high-risk lesions of patients with angiographic follow-up available
All patients with angiographic follow-up Patients with clinically driven angiography Patients with non-clinically driven angiography
Genouos (n 5 53,
L 5 70)
Taxus Liberte ´
(n 5 37, L 5 53)
P-value Genouos (n 5 18,
L 5 22)
Taxus Liberte ´
(n 5 7, L 5 11)
P-value Genouos (n 5 35,
L 5 48)
Taxus Liberte ´
(n 5 30, L 5 42)
P-value
Pre-procedure
Reference vessel
diameter
2.74+0.5 2.69+0.47 0.623 2.81+0.49 2.67+0.6 0.477 2.70+0.51 2.70+0.45 0.968
Minimal lumen
diameter
0.54+0.41 0.61+0.41 0.325 0.53+0.43 0.85+0.37 0.044 0.54+0.41 0.55+0.39 0.926
Percentage diameter
stenosis
79+15 76+15 0.220 80+16 65+17 0.019 79+15 78+14 0.903
Post-procedure
Reference vessel
diameter
2.82+0.46 2.78+0.46 0.620 2.88+0.44 2.71+0.61 0.376 2.79+0.47 2.80+0.42 0.979
Minimal lumen
diameter
2.63+0.34 2.61+0.50 0.889 2.64+0.39 2.52+0.55 0.428 2.62+0.32 2.64+0.49 0.816
Percentage diameter
stenosis
7+58 +7 0.676 10+67 +7 0.301 6+48 +7 0.144
At follow-up
Reference vessel
diameter
2.48+0.48 2.71+0.48 0.011 2.44+0.62 2.56+0.54 0.597 2.49+0.42 2.74+0.46 0.008
Minimal lumen
diameter
1.48+0.73 2.06+0.69 ,0.0001 1.24+0.75 1.92+0.69 0.022 1.59+0.71 2.10+0.70 0.001
Percentage diameter
stenosis
41+25 24+21 ,0.0001 49+23 26+19 0.006 38+25 23+22 0.007
Late loss 1.14+0.64 0.55+0.61 ,0.0001 1.40+0.65 0.60+0.54 0.002 1.03+0.60 0.54+0.62 ,0.0001
n, number of patients; L, number of lesions.
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1comparable to our population albeit the rate of B2/C lesions was
substantial higher in our study (89 vs. 56%). At 1 year, the clinical
outcomes of the Genous stent group in our study were compar-
able to the ﬁndings of Miglionico et al. and add evidence of the
Genous stent in a complex patient and lesion subset. Although
no deﬁnite stent thromboses occurred in the Genous stent
group, a non-signiﬁcant higher rate of repeat revascularization
was observed compared with the Taxus stent stent group in our
study. The difference in the occurrence of stent thrombosis
between the groups was remarkably as the percentage of patients
on dual antiplatelet therapy was signiﬁcantly lower in recipients of
the Genous stent in our study. Theoretically, the Genous stent
may be an attractive alternative to DES or BMS in patients with
an increased risk of stent thrombosis, with a contraindication for
dual antiplatelet therapy, with a (recent) history of bleeding or
for patients that are scheduled for surgery.
Angiographic follow-up data of the Genous stent is limited. In
the HEALING FIM study,
11 non-complex lesions treated with the
Genous stent showed a late loss of 0.63+0.52 mm at 9 months
angiographic follow-up. Interestingly, in the HEALING II
study,
12,13 a signiﬁcant regression of neointimal tissue was
observed in the Genous stents between 6 and 18 months
follow-up by QCA (late loss 0.71+0.35 vs. 0.59+0.31 mm;
P ¼ 0.002). Noteworthy, regarding restenosis, long-term QCA
and IVUS follow-up showed a late catch-up phenomenon after
DES placement, whereas neointimal hyperplasia regression (up
to 10%) was observed after BMS.
19,20 In a subset of 31 patients,
Miglionico et al.
18 performed repeat coronary angiography
between 6 and 8 months independently of clinical recurrence
and observed a late loss of 0.88+0.66 mm. The late loss of the
Genous stent in our study was higher than that observed in
HEALING-FIM, HEALING II, and Miglionico et al., which may be
related to the more complex clinical and/or angiographic charac-
teristics of our patients. Furthermore, angiography was only avail-
able in 47% of the patients because consent for follow-up
angiography was not mandatory for enrolment. Therefore, some
selection bias might have taken place. As our study is small, our
results should be interpreted as ﬁrst indications concerning the
difference in late loss between the Genous group and the Taxus
stent group.
Drug-eluting stents are associated with excessive inhibition of
vascular cell proliferation which may lead to rare but serious com-
plications such as late incomplete stent apposition, aneurysm for-
mation, and late or very late stent thrombosis due to impaired
re-endothelialization.
21,22 A ‘pro-healing’ approach for prevention
of in-stent restenosis is intuitively favoured over the use of cyto-
toxic or cytostatic drugs released from a DES. Circulating EPCs
are able to differentiate into endothelial cells and contribute to
postnatal neorevascularization.
23–26 Moreover, EPCs have the
ability to migrate to areas of vascular injury and initiate the arterial
repair response, thereby improving tissue recovery and blood
ﬂow.
23,27 Low baseline levels of circulating EPCs appears to corre-
late with angiographically documented CAD, in-stent restenosis,
abnormal endothelial function, and prospectively predict an
increase in cardiovascular mortality.
27–31 Furthermore, studies
have shown that patients with cardiovascular risk factors
such as hyperlipidaemia,
32 hypertension,
33 diabetes mellitus,
34,35
smoking,
36malegender,
37andadvancedage
38havedecreasedquan-
tity and quality of circulating EPCs. The main triggers of EPC mobil-
ization are ischemia and vascular injury.
39–41 HMG-CoA reductase
inhibitors (statins) can mobilize and improve the function of EPCs in
patient with stable CAD.
33,42,43 In the HEALING II study,
13 low
levels of circulating EPCs in the peripheral blood were associated
with worse angiographic outcome at 6 months compared with
patients with normal EPC levels. Interestingly, patients who were
on statin therapy had a two-fold higher level of circulating EPCs
and showed a betterclinical outcomeupto 18 months offollow-up.
Therefore, patients included in our study were required to be on
statin therapy for at least 1 week prior to the index procedure.
Importantly, the Genous technology is dependent on the number
and functionality of the EPCs in the circulation, although we did
not measure EPCs in our study.
The present study is a single-centre study and lacks the obvious
advantages of a multicentre, international randomized study.
Owing to small patient numbers, our study was not powered for
robust clinical outcomes assessment. Moreover, no systematic
angiographic follow-up was performed and therefore angiographic
data have to be interpreted with caution. In addition, for the QCA
results presented in the paper, we have assumed that all lesions
were statistically independent. Since the vast majority of the
patients had only one lesion, we considered this a reasonable
assumption. However, the online supplement (see Supplementary
material online, Table S6) contains results that have been adjusted
for the clustering of lesions within patient. Although these results
do not differ qualitatively from the results presented in the printed
form of the paper, the adjusted analyses provide a better approxi-
mation of the between group variation so the adjusted estimates
should be considered if these data are used for study planning
purposes.
To increase patient recruitment and without awaiting the 1 year
clinical results, the single-centre study was transformed into a mul-
ticentre, international study. In the two-armed TRIAS Program,
Figure 3 Cumulative frequency distribution curve. Percentage
diameter stenosis of the high-risk lesions of Genous stent
treated patients (70 lesions in 53 patients) and the Taxus
Liberte ´ stent treated patients (53 lesions in 37 patients) with
complete QCA data.
M.A.M. Beijk et al. 10621260 patients with lesions carrying a high risk of restenosis will be
randomized between a Genous stent and a DES (TRIAS HR trial).
Similarly, 1300 patients with lesions carrying a low risk of resteno-
sis will be randomized between a Genous stent and a BMS (TRIAS
LR trial).
In conclusion, this ﬁrst randomized, single-centre study showed
a non-signiﬁcant higher rate of repeat revascularization in the
Genous stent compared with the Taxus stent in patients treated
for a coronary artery stenosis carrying a high risk of restenosis.
In contrast, more stent thromboses occurred in the Taxus stent
group. The balance between the occurrence of clinical restenosis
vs. the risk of late and very late stent thrombosis and the impact
on short and long-term patient outcome will be investigated in a
larger setting.
Supplementary material
Supplementary material is available at European Heart Journal
online.
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